title: Obstetric outcomes of human immunodeficiency virus-1-serodiscordant couples following in vitro fertilization with intracytoplasmic sperm injection.
abstract: The objective of this article is to report obstetric outcomes of human immunodeficiency virus-1 (HIV-1)-serodiscordant couples who underwent in vitro fertilization and embryo transfer (IVF-ET) with intracytoplasmic sperm injection (ICSI) at a tertiary care center. We reviewed the outcomes of seronegative women after IVF-ET with ICSI from January 1, 1997 to June 1, 2002. Serodiscordant couples (n = 25) successfully conceived 27 pregnancies delivering 40 neonates (16 singletons, 9 twins, and 2 triplets). The mean gestational age at delivery was 37 0/7 weeks +/- 3 6/7 weeks (range 26 0/7 to 41 2/7 weeks). The mean birth weight was 2646 g +/- 952 g (range 678 to 4396 g). The cesarean section rate was 70%. Preterm delivery (<37 weeks) occurred in 7 pregnancies, and low birth weight (<2500 g) was observed in 8 pregnancies. There were no HIV-1 seroconversions detected at delivery. One hundred percent of the mothers and offspring were beyond 3 months postpartum and remained seronegative. IVF-ET with ICSI seems safe and effective for serodiscordant couples. Obstetric outcomes are favorable, and HIV-1 infection risk is limited.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, New York Presbyterian Medical Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
authors.forename: Jane
authors.initials: J
authors.lastname: Cleary-Goldman
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Peña
authors.forename: Melvin H
authors.initials: MH
authors.lastname: Thornton
authors.forename: Julian N
authors.initials: JN
authors.lastname: Robinson
authors.forename: Mary E
authors.initials: ME
authors.lastname: D'Alton
authors.forename: Mark V
authors.initials: MV
authors.lastname: Sauer
mesh_terms: D015492:AIDS Serodiagnosis; D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005865:Gestational Age; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D018023:HIV Seronegativity; D006679:HIV Seropositivity; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011256:Pregnancy Outcome; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D020554:Sperm Injections, Intracytoplasmic / Q000009:adverse effects / Q000379:methods*